Darren McKerrecher
Overview
Explore the profile of Darren McKerrecher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McCoull W, Thomson C, Braybrooke E, Chan C, Colclough N, Cortes Gonzalez M, et al.
J Med Chem
. 2025 Jan;
68(3):3700-3748.
PMID: 39869768
Despite recent advances in the inhibition of EGFR (epidermal growth factor receptor), there remains a clinical need for new EGFR Exon20 insertion (Ex20Ins) inhibitors that spare EGFR WT. Herein, we...
2.
Finlay M, Barton P, Bickerton S, Bista M, Colclough N, Cross D, et al.
J Med Chem
. 2021 Sep;
64(18):13704-13718.
PMID: 34491761
The epidermal growth factor receptor (EGFR) harboring activating mutations is a clinically validated target in non-small-cell lung cancer, and a number of inhibitors of the EGFR tyrosine kinase domain, including...
3.
Ward R, Fawell S, Floch N, Flemington V, McKerrecher D, Smith P
Chem Rev
. 2020 Jul;
121(6):3297-3351.
PMID: 32692162
There has been huge progress in the discovery of targeted cancer therapies in recent years. However, even for the most successful and impactful cancer drugs which have been approved, both...
4.
Floch N, Martin M, Riess J, Orme J, Staniszewska A, Menard L, et al.
Mol Cancer Ther
. 2018 Feb;
17(5):885-896.
PMID: 29483211
EGFR exon 20 insertions (Ex20Ins) account for 4% to 10% of EGFR activating mutations in non-small cell lung cancer (NSCLC). EGFR Ex20Ins tumors are generally unresponsive to first- and second-generation...
5.
Scott J, Bowker S, Brocklehurst K, Brown H, Clarke D, Easter A, et al.
J Med Chem
. 2014 Oct;
57(21):8984-98.
PMID: 25286150
Agonism of GPR119 is viewed as a potential therapeutic approach for the treatment of type II diabetes and other elements of metabolic syndrome. During progression of a previously disclosed candidate...
6.
Scott J, Brocklehurst K, Brown H, Clarke D, Coe H, Groombridge S, et al.
Bioorg Med Chem Lett
. 2013 May;
23(11):3175-9.
PMID: 23628336
A series of conformationally restricted GPR119 agonists were prepared based around a 3,8-diazabicyclo[3.2.1]octane scaffold. Examples were found to have markedly different pharmacology in mouse and human despite similar levels of...
7.
8.
Robb G, McKerrecher D, Newcombe N, Waring M
Drug Discov Today
. 2012 Sep;
18(3-4):141-7.
PMID: 22982302
At AstraZeneca a focus on hypothesis-driven design and the formation of drug design teams has placed a greater emphasis on collaboration in the drug discovery process. We have created a...
9.
Scott J, Birch A, Brocklehurst K, Broo A, Brown H, Butlin R, et al.
J Med Chem
. 2012 May;
55(11):5361-79.
PMID: 22545772
G protein coupled receptor 119 (GPR119) is viewed as an attractive target for the treatment of type 2 diabetes and other elements of the metabolic syndrome. During a program toward...
10.
Brocklehurst K, Broo A, Butlin R, Brown H, Clarke D, Davidsson O, et al.
Bioorg Med Chem Lett
. 2011 Nov;
21(24):7310-6.
PMID: 22061639
GPR119 is increasingly seen as an attractive target for the treatment of type II diabetes and other elements of the metabolic syndrome. During a programme aimed at developing agonists of...